CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
REVENUES:
License fees	$ 1,172,860	$ 2,218,174	$ 899,998
Royalties from product sales	397,751	366,775	541,681
Grant income	3,296,832	1,573,329	2,222,458
Sale of research products and services	375,761	276,058	251,190
Total revenues	5,243,204	4,434,336	3,915,327
Cost of sales	(837,052)	(792,659)	(434,271)
Gross Profit	4,406,152	3,641,677	3,481,056
EXPENSES:
Research and development	(37,532,624)	(26,609,423)	(18,116,688)
Acquired in-process research and development	0	(17,458,766)	0
General and administrative	(17,556,102)	(15,558,674)	(10,365,045)
Total operating expenses	(55,088,726)	(59,626,863)	(28,481,733)
Loss from operations	(50,682,574)	(55,985,186)	(25,000,677)
OTHER EXPENSES:
Interest (expense)/income, net	(88,496)	(578)	19,383
(Loss)/gain on sale or write off of fixed assets	(8,926)	5,120	(6,856)
Other expense, net	(374,715)	(209,177)	(317,710)
Total other expenses, net	(472,137)	(204,635)	(305,183)
LOSS BEFORE INCOME TAX BENEFITS	(51,154,711)	(56,189,821)	(25,305,860)
Deferred income tax benefit	7,375,611	3,280,695	0
NET LOSS	(43,779,100)	(52,909,126)	(25,305,860)
Net loss attributable to non-controlling interest	7,367,440	9,026,291	3,880,157
COMPREHENSIVE LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	(36,411,660)	(43,882,835)	(21,425,703)
Dividends on preferred shares	(86,827)	0	0
Net loss attributable to BioTime, Inc. common shareholders	$ (36,498,487)	$ (43,882,835)	$ (21,425,703)
BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share)	$ (0.55)	$ (0.81)	$ (0.44)
WEIGHTED AVERAGE NUMBER OF COMMON STOCK OUTSTANDING: BASIC AND DILUTED (in shares)	66,466,714	54,226,219	49,213,687